Our top pick for
Building a portfolio
Cabaletta Bio, Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 33 staff and has a market cap (total outstanding shares value) of USD$265.4 million.
|52-week range||USD$6.15 - USD$16.38|
|50-day moving average||USD$11.2817|
|200-day moving average||USD$12.4545|
|Wall St. target price||USD$22.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.9376|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-16.51%|
|Return on equity TTM||-26.9%|
|Market capitalisation||USD$265.4 million|
TTM: trailing 12 months
There are currently 1.7 million Cabaletta Bio shares held short by investors – that's known as Cabaletta Bio's "short interest". This figure is 1.6% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Cabaletta Bio shares can be evaluated.
Cabaletta Bio's "short interest ratio" (SIR) is the quantity of Cabaletta Bio shares currently shorted divided by the average quantity of Cabaletta Bio shares traded daily (recently around 110692.25396825). Cabaletta Bio's SIR currently stands at 15.75. In other words for every 100,000 Cabaletta Bio shares traded daily on the market, roughly 15750 shares are currently held short.
However Cabaletta Bio's short interest can also be evaluated against the total number of Cabaletta Bio shares, or, against the total number of tradable Cabaletta Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cabaletta Bio's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cabaletta Bio shares in existence, roughly 70 shares are currently held short) or 0.0907% of the tradable shares (for every 100,000 tradable Cabaletta Bio shares, roughly 91 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cabaletta Bio.
Find out more about how you can short Cabaletta Bio stock.
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.